1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,640 | 3,050 | 11:59 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.08. | Biohit Oyj Reports Rise In H1 Bottom Line | 2 | RTTNews | ||
| 05.08. | Biohit Oyj: Biohit Group Half Year Financial Report 2026 (unaudited) | 153 | GlobeNewswire (Europe) | BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2026 (unaudited)
Biohit Oyj Half Year Financial Report 5 August 2026 at 9:30 am local time (EET)
SUMMARY
January-June 2026
Revenue EUR 7.8 million (EUR 7.4... ► Artikel lesen | |
| 03.06. | Biohit Oyj: Decisions of the Annual General Meeting of Biohit Oyj | 144 | GlobeNewswire (Europe) | Decisions of the Annual General Meeting of Biohit Oyj
Biohit Oyj Decisions of the Annual General Meeting, June 3, 2026 at 6.00 pm local time (EET)
The Annual General Meeting (AGM) of Biohit Oyj held... ► Artikel lesen | |
| 11.02. | Biohit Oyj: Biohit Group Financial Statement Release 2025 | 233 | GlobeNewswire (Europe) | BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2025 (unaudited)
Biohit Oyj Financial Statement Release 11 February 2026 at 9:30 am local time (EET)
SUMMARY
January-December 2025
Revenue EUR 15.7 million... ► Artikel lesen | |
| 08.12.25 | Biohit Oyj: New Study Shows Normal GastroPanel Result Safely Rules Out Need for Gastroscopy | 217 | GlobeNewswire (Europe) | Biohit Oyj Press Release8 December 2025 at 10:30 a.m. EEST
New Study Shows Normal GastroPanel® Result Safely Rules Out Need for Gastroscopy
Major Cost Savings Possible
A newly published clinical study... ► Artikel lesen | |
| BIOHIT Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | Biohit Oyj: Chile's national cancer prevention strategy brings GastroPanel technology into public healthcare | 336 | GlobeNewswire (Europe) | Biohit Oyj Press Release12 November 2025 at 2:00 p.m. EEST
Chile's national cancer prevention strategy brings GastroPanel® technology into public healthcare
The Chilean Ministry of Health has introduced... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERA THERAPEUTICS | 31,630 | 0,00 % | Goldman Sachs lowers Vera Therapeutics stock price target to $80 | ||
| SUMMIT THERAPEUTICS | 13,350 | 0,00 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| APOGEE THERAPEUTICS | 134,56 | 0,00 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| ERASCA | 18,390 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 367,40 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 21,625 | 0,00 % | Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX, | LONDON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 27, 2026, driven by key catalysts including prospective clinical trial results, and the launch of new services.Dyne... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,610 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,950 | 0,00 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| KYMERA THERAPEUTICS | 117,37 | 0,00 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| CLIMB BIO | 16,340 | 0,00 % | Climb Bio, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 75,10 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,690 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,195 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 76,69 | 0,00 % | Kiniksa auf Wachstumskurs: ARCALYST-Umsatz steigt, Pipeline wird ausgebaut | ||
| BEAM THERAPEUTICS | 26,740 | 0,00 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy |
Das Unternehmen BIOHIT OYJ kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,005 (-0,18 %) liegt der Kurs bei 2,845 Euro. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOHIT OYJ finden Sie auf Wallstreet Online.